0001171843-19-005055.txt : 20190801 0001171843-19-005055.hdr.sgml : 20190801 20190801071641 ACCESSION NUMBER: 0001171843-19-005055 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20190801 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190801 DATE AS OF CHANGE: 20190801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AKORN INC CENTRAL INDEX KEY: 0000003116 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 720717400 STATE OF INCORPORATION: LA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32360 FILM NUMBER: 19990904 BUSINESS ADDRESS: STREET 1: 1925 W. FIELD COURT, SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 BUSINESS PHONE: 847-279-6100 MAIL ADDRESS: STREET 1: 1925 W. FIELD COURT, SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 8-K 1 f8k_080119.htm FORM 8-K Form 8-K
0000003116 False 0000003116 2019-08-01 2019-08-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 1, 2019

_______________________________

Akorn, Inc.
AKORN INC
(Exact name of registrant as specified in its charter)

_______________________________

Louisiana 001-32360 72-0717400
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

1925 W. Field Court, Suite 300
Lake Forest, Illinois 60045

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (847) 279-6100

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, No Par Value AKRX The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 1, 2019, Akorn, Inc. (the “Company”) issued a press release announcing preliminary financial results as of and for the three and six month periods ended June 30, 2019.  A copy of the press release is furnished as Exhibit 99.1 to this report.

 

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Cautionary Note Regarding Forward-Looking Statements

 

This report includes statements that may constitute "forward-looking statements", including expectations regarding the Company’s business plan and initiatives, financial performance, product launches, pending ANDA filings, the financial guidance for 2019, the non-binding agreement in principle to settle the Securities Class Action Litigation, and other statements regarding the Company’s plans and strategy. When used in this document, the words “will,” “expect,” “continue," “believe,” “anticipate,” “estimate,” “intend,” “could,” “strives” and similar expressions are generally intended to identify forward-looking statements. These statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. A number of important factors could cause actual results of the Company and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to:  (i) the effect of the Delaware Court of Chancery’s October 1, 2018 decision against the Company and the Delaware Supreme Court’s December 7, 2018 order affirming the Chancery Court’s decision on the Company’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally, (ii) the risk that ongoing or future litigation against the defendants or related to the court’s decision may result in significant costs of defense, indemnification and/or liability, (iii) the outcome of the investigation conducted by the Company, with the assistance of outside consultants, into alleged breaches of FDA data integrity requirements relating to product development at the Company and any actions taken by the Company, third parties or the FDA as a result of such investigations, (iv) the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any, (v) the timing and success of product launches, (vi) difficulties or delays in manufacturing, (vii) the Company’s increased indebtedness and obligation to comply with certain covenants and other obligations under its standstill agreement with its first lien term loan lenders (the “Standstill Agreement”), (viii) the Company’s obligation under the Standstill Agreement to enter into a comprehensive amendment that is satisfactory in form and substance to the first lien term loan lenders, (ix) the risk that the parties will not enter into a definitive settlement agreement in connection with the Securities Class Action Litigation, (x) the risk that the holders of a significant number of shares may opt out of and elect not to participate in or be bound by the proposed Securities Class Action Litigation settlement, (xi) the risk that a definitive settlement agreement in connection the with Securities Class Action Litigation may not obtain the necessary approval by the court or may be terminated in accordance with its terms, (xii) the risk that insurance proceeds, common shares or other consideration contemplated to be exchanged pursuant to the proposed Securities Class Action Litigation settlement is not available at the appropriate time and (xiii) such other risks and uncertainties outlined in the risk factors detailed in Part I, Item 1A, “Risk Factors,” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (as filed with the Securities and Exchange Commission (“SEC”) on March 1, 2019) and in Part II, Item 1A, “Risk Factors,” of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019 (as filed with the SEC on May 9, 2019) and other risk factors identified from time to time in the Company’s filings with the SEC. Readers should carefully review these risk factors, and should not place undue reliance on the Company’s forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this report. The Company undertakes no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) The following exhibit is filed as part of this report:

 

Exhibit No.

  

Description of Exhibit

99.1   Press release dated August 1, 2019, entitled “Akorn Provides Preliminary Second Quarter 2019 Results.”

 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   
    Akorn, Inc.
     
Date: August 1, 2019 By:  /s/ Duane A. Portwood
    Duane A. Portwood
    Chief Financial Officer
     

 

 

 EX-99.1 2 exh_991.htm EXHIBIT 99.1 EdgarFiling

EXHIBIT 99.1

Akorn Provides Preliminary Second Quarter 2019 Results

LAKE FOREST, Ill., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its preliminary financial results for the second quarter of 2019.

Second Quarter 2019 and Recent Business Highlights

  • Net revenue was $178 million, up 7% from the first quarter of 2019, down 7% from the prior year quarter
  • Net loss was $112 million, compared to $82 million in the first quarter of 2019 and $88 million in the prior year quarter
  • Adjusted EBITDA was $22 million, compared to $10 million in the first quarter of 2019 and $35 million in the prior year quarter
  • Generated positive operating cash flow during the second quarter
  • Continued sequential reduction in backorders and failure to supply penalties
  • Launched three products:  TheraTears® SteriLid® Antimicrobial, the first FDA Accepted Antimicrobial Eyelid Cleanser, Loteprednol Etabonate Ophthalmic Suspension, 0.5%, and Dicyclomine Hydrochloride Injection, USP
  • Received three ANDA approvals: Loteprednol Etabonate Ophthalmic Suspension, 0.5%, Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC), and Azelastine Hydrochloride Nasal Spray, 0.1%
  • Responded to FDA warning letter related to the 2018 inspection of our Somerset, NJ manufacturing facility
  • Reached non-binding agreement in principle with lead plaintiffs in the securities class action litigation

See "Non-GAAP Financial Measures" below.

Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “We are pleased that our second quarter results showed continued financial and operational improvements across the business, a strong signal that our operational initiatives are creating value and generating momentum.  We saw reductions in backorders and failure to supply penalties, which have a direct impact on both financial performance and customer satisfaction.”

Boothe continued, “As we look to the second half of 2019, we feel confident in the fundamentals of our business and believe that our focus on compliance, transparency, and accountability will allow us to execute against our strategic growth objectives.  As such, we are updating our net loss guidance and affirming our net revenue and adjusted EBITDA guidance for the full year of 2019 as we strive to return the Company to a path of long-term profitable growth for our stakeholders.”

Summary Financial Results for the Quarter Ended June 30, 2019

Akorn reported net revenue of $178.1 million for the three month period ended June 30, 2019, representing a decrease of $12.8 million, or 6.7%, as compared to net revenue of $190.9 million for the three month period ended June 30, 2018.  The decrease in net revenue in the period was primarily due to $15.0 million decline in organic revenue that was partially offset by $2.6 million net revenue increase in new products and product relaunches.  The $15.0 million decline in organic revenue was due to approximately $29.2 million, or 15.3% in volume declines partially offset by $14.2 million, or 7.5%, of favorable price variance.  The volume decline was principally due to the effect of competition on a number of products, including Fluticasone Rx, Methylene Blue and Clobetasol Cream, as well as supply shortfalls from the continued production ramp-up at our Somerset manufacturing facility.

Consolidated gross profit for the quarter ended June 30, 2019, was $68.0 million, or 38.2% of net revenue, compared to $81.3 million, or 42.6% of net revenue, in the corresponding prior year quarter.  The decline in the gross profit percentage was principally due to increased operating costs associated with FDA compliance related improvement activities as well as increased inventory loss that was partially offset by favorable price and product mix.

GAAP net loss for the second quarter of 2019, was $111.6 million, or $(0.89) per diluted share, compared to GAAP net loss of $88.0 million, or $(0.70) per diluted share, for the same quarter of 2018.  After a net adjustment of $109 million to net loss for non-GAAP items, adjusted diluted earnings per share for the second quarter of 2019 were $(0.02), compared to $0.10 in the same quarter of 2018, after a net adjustment of $101 million to net income for non-GAAP items.  See "Non-GAAP Financial Measures" below.

Earnings before interest, taxes, depreciation and amortization (EBITDA) was $(75.4) million for the second quarter of 2019, compared to $(73.0) million for the second quarter of 2018.  Adjusted EBITDA, which is a non-GAAP measure used by management to evaluate the performance of the Akorn business, was $21.8 million for the second quarter of 2019, compared to $34.8 million for the second quarter of 2018.  See "Non-GAAP Financial Measures" below.

Summary Financial Results for the Six Months Ended June 30, 2019

Akorn reported net revenue of $343.9 million for the six month period ended June 30, 2019, representing a decrease of $31.1 million, or 8.3%, as compared to net revenue of $375.0 million for the six month period ended June 30, 2018.  The decrease in net revenue in the period was primarily due to $33.1 million decline in organic revenue that was partially offset by $3.3 million net revenue increase in new products and product relaunches.  The $33.1 million decline in organic revenue was due to approximately $56.8 million, or 15.2% in volume declines partially offset by $23.7 million, or 6.3%, of favorable price variance.  The volume decline was principally due to the effect of competition on a number of products, including Nembutal, Fluticasone Rx and Clobetasol Cream and supply shortfalls from the continued production ramp-up at our Somerset manufacturing facility.

Consolidated gross profit for the six month period ended June 30, 2019, was $121.5 million, or 35.3% of net revenue, compared to $163.5 million, or 43.6% of net revenue, in the corresponding prior year period.  The decline in the gross profit percentage was principally due to increased operating costs associated with FDA compliance related improvement activities and increased inventory loss.

GAAP net loss was $193.8 million for the six month period ended June 30, 2019, or $(1.54) per diluted share, compared to GAAP net loss of $116.7 million for the six month period ended June 30, 2018, or $(0.93) per diluted share.  After a net adjustment of $179 million to net income for non-GAAP items, adjusted diluted earnings per share for the six months ended June 30, 2019 were $(0.12), compared to $0.15 in the corresponding period in the prior year, after a net adjustment of $136 million to net income for non-GAAP items.

EBITDA was $(123.1) million for the six month period ended June 30, 2019, compared to $(79.2) million for the six month period ended June 30, 2018.  Adjusted EBITDA, which is a non-GAAP measure used by management to evaluate the performance of the Akorn business, was $31.6 million for the six month period ended June 30, 2019, compared to $59.3 million for the six month period ended June 30, 2018.  See "Non-GAAP Financial Measures" below.

Updated Full Year 2019 Guidance

The Company is affirming its net revenue and adjusted EBITDA guidance, and updating other guidance as noted below:

  • Net revenue for the year is expected to be in the range of $690 to $710 million
  • Net loss for the year is expected to be in the range of ($273) to ($258) million, an increase of $107 million from initial guidance, primarily driven by the estimated charge related to the securities class action litigation non-binding agreement in principle as well as the impact of our previously disclosed Standstill Agreement
  • Adjusted EBITDA for the year is expected to be in the range of $71 to $86 million
  • Expecting approximately $40 million in capital expenditures
  • Expecting approximately $50 million for FDA compliance and data integrity assessment expenditures, an increase of $10 million from initial guidance primarily driven by expected costs related to the Somerset warning letter

Securities Class Action Litigation

As previously disclosed in our Form 8-K filed with the SEC on July 30, 2019, the Company and the lead plaintiffs in In re Akorn, Inc. Data Integrity Securities Litigation (the “Securities Class Action Litigation”) have advised the court presiding over the matter that they have entered into a non-binding agreement in principle to resolve the Securities Class Action Litigation and the claims of the putative class.  As required by generally accepted accounting principles, the Company recorded an estimated charge and corresponding liability of $74 million associated with the non-binding agreement in principle, which is reflected in the Company’s preliminary financial statements for the quarter ended June 30, 2019.  The corresponding liability is expected to be settled through the issuance of currently authorized Company stock and future contingent cash payments subject to the Company exceeding certain profitability thresholds.  In addition, the lead plaintiffs could receive up to $30 million in insurance proceeds under the Company's insurance policies.

Status of Akorn Pending ANDA Filings

As of July 31, 2019, Akorn had 36 ANDAs pending at the FDA, representing approximately $5.6 billion in annual branded and generic market value according to IQVIA.

Filed Tentative ApprovalPendingTotal
$ in millions CountValue *CountValue *CountValue *
OphthalmicBrand **3$45810$3,56113$4,019
 Generic11331114124
InjectableBrand **——210210
 Generic1158694071,099
TopicalBrand **——————
 Generic——472472
OtherBrand **——————
 Generic——63136313
Total 5$63031$5,00836$5,638

*  The value, shown in millions, is the market size estimate based on IQVIA data for the trailing 12 months
 ended May 2019 and excludes any trade and customary allowances and discounts.  The IQVIA market size is not a forecast of our future sales.

** The label "brand" indicates that the pending ANDA filing is for a product that has not yet had generic competition, therefore the market value is that of the branded reference drug.  All filings reported in the table are generic filings.

Conference Call and Webcast Details:

As previously announced, Akorn’s management will hold a conference call with interested investors and analysts at 9:00 a.m. EST on August 1, 2019, to discuss these results and updates in more detail.  The dial-in number to access the call is (844) 249-9382 in the U.S. and Canada and +1 (270) 823-1530 for international callers.  The conference ID is 7567263.  To access the live webcast, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.  A webcast replay of the conference call will be available shortly following the conclusion of the call and will be available for 90 days following the call.  To access the webcast replay, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

About Akorn:

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals.  Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals.  Additional information is available on Akorn’s website at www.akorn.com.

Non-GAAP Financial Measures:

To supplement Akorn’s financial results presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses certain non-GAAP (also referred to as “adjusted” or “non-GAAP adjusted”) financial measures in this press release and the accompanying tables, including (1) EBITDA, (2) adjusted EBITDA, (3) adjusted net income, (4) adjusted diluted earnings per share, (5) net debt, and (6) net debt to adjusted EBITDA ratio.  These non-GAAP measures adjust for certain specified items that are described in this release.  The Company believes that each of these non-GAAP financial measures is helpful in understanding its past financial performance and potential future results.  The non-GAAP financial measures are not meant to be considered in isolation or as a substitute for or superior to comparable GAAP measures.

Akorn’s management uses these measures in analyzing its business and financial condition.  Akorn’s management believes that the presentation of these and other non-GAAP financial measures provide investors greater transparency into Akorn’s ongoing results of operations allowing investors to better compare the Company’s results from period to period.

Investors should note that these non-GAAP financial measures used to present financial guidance are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP.  Investors should also note that these non-GAAP financial measures have no standardized meaning prescribed by GAAP and; therefore, have limits in their usefulness to investors.  In addition, from time-to-time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; likewise, the Company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures.  Because of the non-standardized definitions, the non-GAAP financial measures as used by Akorn in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the Company’s competitors and other companies.

Set forth below is the definition of each non-GAAP financial measure as used by the Company in this press release and a full reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measures.

EBITDA, as defined by the Company, represents net (loss) income before net interest income (expense),
provision (benefit) for income taxes and depreciation and amortization.

Adjusted EBITDA, as defined by the Company, is calculated as follows:

Net (loss) income, (minus) plus:

Interest income (expense), net
Provision (benefit) for income taxes
Depreciation and amortization
Non-cash expenses, such as impairment of long-lived assets, share-based compensation expense, and amortization of deferred financing costs
Other adjustments, such as legal settlements, restatement expenses and various merger and acquisition-related expenses, employee retention expense, refinancing advisory fees, fixed asset impairment, executive termination expenses, data integrity investigations & assessment, gain on disposal of fixed assets, and
Fresenius transaction & litigation

Adjusted EBITDA is deemed by the Company to be a useful performance indicator because it includes an add back of non-cash or non-recurring operating expenses that have no impact on continuing cash flows as well as other items that are not expected to recur and therefore are not reflective of continuing operating performance.

Adjusted net (loss) income, as defined by the Company, is calculated as follows:

Net (loss) income, (minus) plus:

Amortization expense
Non-cash expenses, such as impairment of long-lived assets, share-based compensation expense, and amortization of deferred financing costs
Other adjustments, such as legal settlements, restatement expenses and various merger and acquisition-related expenses, employee retention expense, refinancing advisory fees, fixed asset impairment, executive termination expenses, data integrity investigations & assessment, gain on disposal of fixed assets, and
Fresenius transaction & litigation
Less an estimated tax provision, net of the benefit from utilizing net operating loss carry-forwards effected for the adjustments noted above

Adjusted diluted earnings per share, as defined by the Company, is equal to adjusted net income divided by the actual or anticipated diluted share count for the applicable period.  The Company believes that adjusted net income and adjusted diluted earnings per share are meaningful financial indicators, to both Company management and investors, in that they exclude non-cash income and expense items that have no impact on current or future cash flows, as well as other income and expense items that are not expected to recur and therefore are not reflective of continuing operating performance.

Net debt, as defined by the Company, is gross debt including Akorn’s term loan and revolving debt balances (if applicable) less cash and cash equivalents.

Net debt to adjusted EBITDA ratio, as defined by the Company, is net debt divided by the trailing twelve months adjusted EBITDA.

The shortcomings of non-GAAP financial measures as guidance or performance measures are that they provide a view of the Company’s results of operations without including all events during a period.  For example, adjusted EBITDA does not take into account the impact of capital expenditures on either the liquidity or the financial performance of the Company and likewise omits share-based compensation expenses, which may vary over time and may represent a material portion of overall compensation expense.  Adjusted net income does not take into account non-cash expenses that reflect the amortization of past expenditures, or include share-based compensation, which is an important and material element of the Company's compensation package for its directors, officers and other key employees.  Due to the inherent limitations of non-GAAP financial measures, investors should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.  Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures as presented in this press release.

Cautionary Note Regarding Forward-Looking Statements

This press release includes statements that may constitute "forward-looking statements", including expectations regarding the Company’s business plan and initiatives, financial performance, product launches, pending ANDA filings, the financial guidance for 2019, the non-binding agreement in principle to settle the Securities Class Action Litigation, and other statements regarding the Company’s plans and strategy.  When used in this document, the words “will,” “expect,” “continue," “believe,” “anticipate,” “estimate,” “intend,” “could,” “strives” and similar expressions are generally intended to identify forward-looking statements.  These statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  A number of important factors could cause actual results of the Company and its subsidiaries to differ materially from those indicated by such forward-looking statements.  These factors include, but are not limited to:  (i) the effect of the Delaware Court of Chancery’s October 1, 2018 decision against the Company and the Delaware Supreme Court’s December 7, 2018 order affirming the Chancery Court’s decision on the Company’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally, (ii) the risk that ongoing or future litigation against the defendants or related to the court’s decision may result in significant costs of defense, indemnification and/or liability, (iii) the outcome of the investigation conducted by the Company, with the assistance of outside consultants, into alleged breaches of FDA data integrity requirements relating to product development at the Company and any actions taken by the Company, third parties or the FDA as a result of such investigations, (iv) the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any, (v) the timing and success of product launches, (vi) difficulties or delays in manufacturing, (vii) the Company’s increased indebtedness and obligation to comply with certain covenants and other obligations under its standstill agreement with its first lien term loan lenders (the “Standstill Agreement”), (viii) the Company’s obligation under the Standstill Agreement to enter into a comprehensive amendment that is satisfactory in form and substance to the first lien term loan lenders, (ix) the risk that the parties will not enter into a definitive settlement agreement in connection with the Securities Class Action Litigation, (x) the risk that the holders of a significant number of shares may opt out of and elect not to participate in or be bound by the proposed Securities Class Action Litigation settlement, (xi) the risk that a definitive settlement agreement in connection the with Securities Class Action Litigation may not obtain the necessary approval by the court or may be terminated in accordance with its terms, (xii) the risk that insurance proceeds, common shares or other consideration contemplated to be exchanged pursuant to the proposed Securities Class Action Litigation settlement is not available at the appropriate time and (xiii) such other risks and uncertainties outlined in the risk factors detailed in Part I, Item 1A, “Risk Factors,” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (as filed with the Securities and Exchange Commission (“SEC”) on March 1, 2019) and in Part II, Item 1A, “Risk Factors,” of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019 (as filed with the SEC on May 9, 2019) and other risk factors identified from time to time in the Company’s filings with the SEC.  Readers should carefully review these risk factors, and should not place undue reliance on the Company’s forward-looking statements.  These forward-looking statements are based on information, plans and estimates at the date of this press release.  The Company undertakes no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.


AKORN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS)
(In Thousands, Except Per Share Data)
(Unaudited)

 Three Months Ended
June 30,		 Six Months Ended
June 30,
 2019 2018 2019 2018
Revenues, net$178,057  $190,944  $343,928  $375,007 
Cost of sales (exclusive of amortization of intangibles, included within operating expenses below)110,073  109,665  222,431  211,500 
GROSS PROFIT67,984  81,279  121,497  163,507 
        
Selling, general and administrative expenses61,042  83,758  133,540  146,752 
Research and development expenses9,495  11,371  18,209  24,015 
Amortization of intangibles9,950  13,182  21,015  26,372 
Impairment of goodwill—  —  15,955  — 
Impairment of intangible assets394  64,534  10,748  83,349 
Litigation rulings, settlements and contingencies74,469  (400) 74,879  (400)
TOTAL OPERATING EXPENSES155,350  172,445  274,346  280,088 
OPERATING (LOSS)(87,366) (91,166) (152,849) (116,581)
Amortization of deferred financing costs(5,655) (1,304) (6,959) (2,608)
Interest expense, net(17,341) (11,062) (31,668) (20,640)
Other non-operating income (loss), net245  (724) 598  (454)
        
(LOSS) BEFORE INCOME TAXES(110,117) (104,256) (190,878) (140,283)
Income tax provision (benefit)1,482  (16,272) 2,902  (23,552)
        
NET (LOSS)$(111,599) $(87,984) $(193,780) $(116,731)
NET (LOSS) PER SHARE       
NET (LOSS) PER SHARE, BASIC$(0.89) $(0.70) $(1.54) $(0.93)
NET (LOSS) PER SHARE, DILUTED$(0.89) $(0.70) $(1.54) $(0.93)
        
SHARES USED IN COMPUTING NET (LOSS) PER SHARE       
BASIC126,043  125,332  125,806  125,286 
DILUTED126,043  125,332  125,806  125,286 
        
COMPREHENSIVE (LOSS)       
Net (loss)$(111,599) $(87,984) $(193,780) $(116,731)
Unrealized holding (loss) on available-for-sale securities, net of tax of $1 and $1 for the three month periods ended June 30, 2019 and 2018, and $1 and $1 for the six month periods ended June 30, 2019 and 2018, respectively.(3) (4) (3) (5)
Foreign currency translation gain (loss)1,380  (6,350) 956  (7,198)
Pension liability adjustment (loss) gain, net of tax of ($48) and ($1) for the three month periods ended June 30, 2019 and 2018, and ($19) and ($2) for the six month periods ended June 30, 2019 and 2018, respectively.190  4  74  8 
COMPREHENSIVE (LOSS)$(110,032) $(94,334) $(192,753) $(123,926)
 


AKORN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Share Data)

 June 30, 2019
(Unaudited)		 December 31,
2018
ASSETS   
CURRENT ASSETS   
Cash and cash equivalents$178,264  $224,868 
Trade accounts receivable, net172,611  153,126 
Inventories, net162,593  173,645 
Available-for-sale securities, current—  — 
Prepaid expenses and other current assets24,307  32,180 
TOTAL CURRENT ASSETS537,775  583,819 
PROPERTY, PLANT AND EQUIPMENT, NET325,098  334,853 
OTHER LONG-TERM ASSETS   
Goodwill267,923  283,879 
Intangible assets, net253,301  284,976 
Right-of-use assets, net - Operating leases22,542  — 
Deferred tax assets—  — 
Other non-current assets7,520  7,730 
TOTAL OTHER LONG-TERM ASSETS551,286  576,585 
TOTAL ASSETS$1,414,159  $1,495,257 
LIABILITIES AND SHAREHOLDERS’ EQUITY   
CURRENT LIABILITIES   
Trade accounts payable$38,420  $39,570 
Income taxes payable13,955  — 
Accrued royalties5,862  6,786 
Accrued compensation19,762  19,745 
Accrued administrative fees27,453  36,767 
Current portion of accrued legal fees and contingencies82,576  52,413 
Current portion of lease liability - Operating leases2,472  — 
Accrued expenses and other liabilities12,926  15,542 
Current portion of long-term debt (net of deferred financing costs)828,282  — 
TOTAL CURRENT LIABILITIES1,031,708  170,823 
LONG-TERM LIABILITIES   
Long-term debt (net of non-current deferred financing costs)—  820,411 
Deferred tax liability937  566 
Uncertain tax liabilities52,516  49,990 
Long-term lease liability - Operating leases21,877  — 
Long-term portion of accrued legal fees and contingencies38,500  — 
Pension obligations and other liabilities7,469  9,601 
TOTAL LONG-TERM LIABILITIES121,299  880,568 
TOTAL LIABILITIES1,153,007  1,051,391 
SHAREHOLDERS’ EQUITY   
Preferred stock, $1 par value - 5,000,000 shares authorized; no shares issued or outstanding at June 30, 2019 and December 31, 2018.—  — 
Common stock, no par value – 150,000,000 shares authorized; 126,107,933 and 125,492,373 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively.584,592  574,553 
(Accumulated deficit)(300,948) (107,168)
Accumulated other comprehensive (loss)(22,492) (23,519)
TOTAL SHAREHOLDERS’ EQUITY261,152  443,866 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$1,414,159  $1,495,257 
 


AKORN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
(Unaudited)

 Six Months Ended
June 30,
 2019 2018
OPERATING ACTIVITIES:   
Net (loss)$(193,780) $(116,731)
Adjustments to reconcile consolidated net (loss) to net cash (used in) operating activities:   
Depreciation and amortization36,123  40,439 
Amortization of debt financing fees6,959  2,608 
Impairment of intangible assets10,748  83,349 
Goodwill impairment15,955  — 
Fixed asset impairment and other10,227  — 
Non-cash stock compensation expense10,308  11,453 
Non-cash interest expense913  — 
Deferred income taxes, net366  (24,512)
Other(29) 481 
Changes in operating assets and liabilities:   
Other non-current assets440  (28)
Trade accounts receivable(19,496) (45,893)
Inventories, net11,186  (7,735)
Prepaid expenses and other current assets5,977  8,204 
Trade accounts payable2,078  602 
Accrued legal fees and contingencies68,662  15,387 
Uncertain tax liabilities2,526  844 
Accrued expenses and other liabilities1,526  259 
NET CASH (USED IN) OPERATING ACTIVITIES$(29,311) $(31,273)
INVESTING ACTIVITIES:   
Proceeds from disposal of assets—  20 
Payments for intangible assets(87) (50)
Purchases of property, plant and equipment(16,863) (35,862)
NET CASH (USED IN) INVESTING ACTIVITIES$(16,950) $(35,892)
FINANCING ACTIVITIES:   
Proceeds from the exercise of stock options—  254 
Stock compensation plan withholdings for employee taxes(269) — 
Payment of contingent acquisition liabilities—  (4,793)
Lease payments(338) (6)
NET CASH (USED IN) FINANCING ACTIVITIES$(607) $(4,545)
Effect of exchange rate changes on cash and cash equivalents141  (560)
(DECREASE) IN CASH AND CASH EQUIVALENTS$(46,727) $(72,270)
Cash and cash equivalents, and restricted cash at beginning of period225,794  369,889 
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF PERIOD$179,067  $297,619 
SUPPLEMENTAL DISCLOSURES:   
Amount paid for interest$34,179  $25,462 
Amount (received) paid for income taxes, net$(14,859) $9,260 
Additional capital expenditures included in accounts payable$3,277  $12,010 
        


Reconciliation of GAAP Net (Loss) to Non-GAAP EBITDA and Adjusted EBITDA
(In Thousands)
(Unaudited)

 Three Months Ended Six Months Ended
  June 30, June 30,
  2019 2018 2019 2018
NET (LOSS)$(111,599) $(87,984) $(193,780) $(116,731)
         
ADJUSTMENTS TO ARRIVE AT EBITDA:       
 Depreciation expense7,423  6,979  15,108  14,067 
 Amortization expense9,950  13,182  21,015  26,372 
 Interest expense, net17,341  11,062  31,668  20,640 
 Income tax (benefit) provision1,482  (16,272) 2,902  (23,552)
EBITDA(75,403) (73,033) (123,087) (79,204)
         
NON-CASH AND OTHER NON-RECURRING INCOME AND EXPENSES       
 Merger and acquisition-related expenses9  64  6  75 
 Employee retention expense1,585  —  3,343  — 
 Data integrity investigations & assessment3,179  12,428  7,833  16,731 
 Fresenius transaction & litigation1,940  24,857  3,631  25,462 
 Refinancing advisory fees4,290  —  10,038  — 
 Non-cash stock compensation expense5,588  5,945  10,308  11,453 
 Impairment of goodwill—  —  15,955  — 
 Impairment of intangible assets394  64,534  10,748  83,349 
 Amortization of deferred financing costs5,655  1,304  6,959  2,608 
 Restatement expenses—  (904) (26) (814)
 Executive termination expenses—  —  835  — 
 Impairment of fixed assets and other138  —  10,227  — 
 Loss (Gain) on disposal of fixed assets2  3  (29) (2)
 Litigation rulings, settlements and contingencies74,469  (400) 74,879  (400)
         
ADJUSTED EBITDA$21,846  $34,798  $31,620  $59,258 
                

The table below sets forth expenses included in Net (loss) that have not been included as adjustments to arrive at EBITDA and Adjusted EBITDA in the preceding table.

 ($ in thousands) 
 Three Months Ended Six Months Ended
 June 30, June 30,
 2019 2018 2019 2018
FDA compliance related expenses$11,850  $250  22,841  250 
Failure to supply penalties (recorded as a contra-revenue)4,687  $1,536  10,225  11,010 
TheraTears® direct-to-consumer advertising campaign1,528  $1,521  2,434  9,875 
             


Reconciliation of GAAP Net (Loss) to non-GAAP Adjusted Net (Loss) and Adjusted Diluted (Loss) Earnings Per Share
(In Thousands, Except Per Share Data)
(Unaudited)

 Three Months Ended Six Months Ended
 June 30, June 30,
 2019 2018 2019 2018
NET (LOSS)$(111,599) $(87,984) $(193,780) $(116,731)
        
Income tax provision (benefit)1,482  (16,272) 2,902  (23,552)
        
(LOSS) BEFORE INCOME TAXES$(110,117) $(104,256) $(190,878) $(140,283)
        
ADJUSTMENTS TO ARRIVE AT ADJUSTED NET INCOME:       
Merger & acquisition-related expenses (1)9  64  6  75 
Employee retention expense (2, 3, 4)1,585  —  3,343  — 
Data integrity investigations & assessment (2)3,179  12,428  7,833  16,731 
Fresenius transaction & litigation (2)1,940  24,857  3,631  25,462 
Refinancing advisory fees (2)4,290  —  10,038  — 
Restatement expenses (2)—  (904) (26) (814)
Non-cash stock compensation expense (2, 3, 4)5,588  5,945  10,308  11,453 
Amortization expense (5)9,950  13,182  21,015  26,372 
Impairment of goodwill (7)—  —  15,955  — 
Impairment of intangible assets (7)394  64,534  10,748  83,349 
Amortization of deferred financing costs (8)5,655  1,304  6,959  2,608 
Executive termination expenses (2)—  —  835  — 
Impairment of fixed assets and other (9)138  —  10,227  — 
Gain on disposal of fixed assets (2, 6)2  3  (29) (2)
Litigation rulings, settlements and contingencies (10)74,469  (400) 74,879  (400)
ADJUSTED (LOSS) INCOME BEFORE INCOME TAX$(2,918) $16,757  $(15,156) $24,551 
        
Option exercise and RSU vesting tax impact (11)—  (1,138) —  (1,138)
ADJUSTMENTS TO INCOME TAX PROVISION (BENEFIT)—  5,034  —  6,609 
TOTAL ADJUSTED INCOME TAX PROVISION (BENEFIT)$—  $3,896  $—  $5,471 
        
ADJUSTED NET (LOSS)  INCOME$(2,918) $12,861  $(15,156) $19,080 
        
ADJUSTED DILUTED EARNINGS PER SHARE$(0.02) $0.10  $(0.12) $0.15 
        
(1) - Excluded from Acquisition-related costs       
(2) - Excluded from SG&A expenses       
(3) - Excluded from R&D expenses       
(4) - Excluded from Cost of sales       
(5) - Excluded from Amortization of intangibles       
(6) - Excluded from Other non-operating (expense) income, net       
(7) - Excluded from Impairment of goodwill, intangible assets       
(8) - Excluded from Amortization of deferred financing costs       
(9) - Excluded from Impairment of fixed assets       
(10) - Excluded from Litigation rulings, settlements and contingencies       
        


AKORN, INC.
Reconciliation of GAAP Debt to Non-GAAP Net Debt and Net Debt to Adjusted EBITDA Ratio
(In Thousands, Except Net Debt to Adjusted EBITDA Ratio)

 June 30, 2019
GAAP Debt$828,282 
Deferred financing costs15,429 
Total term loans outstanding$843,711 
Cash and cash equivalents178,264 
Net debt$665,447 
  
Adjusted EBITDA, trailing twelve months ended$21,517 
  
Net debt to adjusted EBITDA ratio30.9 
 


AKORN, INC.
Reconciliation of 2019 Financial Guidance of GAAP Net Loss to Non-GAAP Adjusted EBITDA
(In Millions)

 2019 Guidance
 Lower Range Upper Range
NET (LOSS)$(273) $(258)
    
Add:   
Depreciation expense31  31 
Amortization expense40  40 
Interest expense, net69  69 
Income tax (benefit) provision5  5 
EBITDA$(128) $(113)
    
Add:   
Employee retention expense5  5 
Data Integrity investigations & assessment12  12 
Fresenius transaction & litigation6  6 
Non-cash stock compensation expense21  21 
Refinancing advisory fees20  20 
Impairment of goodwill16  16 
Impairment of intangible assets11  11 
Amortization of deferred financing costs22  22 
Executive termination expenses1  1 
Impairment of fixed assets and other10  10 
Litigation rulings, settlements and contingencies75  75 
    
ADJUSTED EBITDA$71  $86 
 

Investors/Media:
(847) 279-6162
Investor.relations@akorn.com

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Class A [Member] Preferred Class A [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 f8k_080119_htm.xml IDEA: XBRL DOCUMENT 0000003116 2019-08-01 2019-08-01 iso4217:USD shares iso4217:USD shares 0000003116 false 8-K 2019-08-01 AKORN INC LA 001-32360 72-0717400 1925 W. Field Court, Suite 300 Lake Forest IL 60045 847 279-6100 false false false false Common Stock, No Par Value AKRX NASDAQ false false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Cover
Aug. 01, 2019
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 01, 2019
Entity File Number 001-32360
Entity Registrant Name AKORN INC
Entity Central Index Key 0000003116
Entity Tax Identification Number 72-0717400
Entity Incorporation, State or Country Code LA
Entity Address, Address Line One 1925 W. Field Court, Suite 300
Entity Address, City or Town Lake Forest
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60045
City Area Code 847
Local Phone Number 279-6100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, No Par Value
Trading Symbol AKRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Elected Not To Use the Extended Transition Period false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 1 97 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_080119.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_080119.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "f8k_080119.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 63, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "f8k_080119.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "f8k_080119.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } ZIP 15 0001171843-19-005055-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-19-005055-xbrl.zip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�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end